A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis

BackgroundSTN1013001 is an innovative latanoprost cationic emulsion for open-angle glaucoma/ocular hypertension (OAG/OHT) and ocular surface disease (OSD).Methods and findingsA 5-year, 7 health states, 1-year cycle early Markov model-supported cost-utility analysis (CUA) of STN1013001 vs. other latanoprost formulations (Latanoprost) followed the Italian National Health Service (INHS) perspective.One-way, probabilistic and scenario sensitivity analyses tested the uncertainty of the baseline results. Value of information analysis (VOIA) investigated the potential cost-effectiveness of collecting further evidence.ResultsOver 5 years, the Markov model-supported CUA predicts STN1013001 to be potentially highly cost-effective vs. Latanoprost (+euro57.60 cost at euro2020 values; +0.089 Quality-Adjusted Life Years).The Incremental Cost-Utility Ratio (euro647.65) falls well below the lower limit of the acceptability range proposed for Italy (euro25,000-euro40,000).Sensitivity analyses confirmed the robustness of the baseline findings. VOIA highlighted that further information might only be cost-effective for OAG/OHT utilities and OSD-related disutility.ConclusionSTN1013001 is potentially highly cost-effective and strongly dominant vs. Latanoprost for OAG/OHT+OSD patients from the INHS perspective. These findings should be re-assessed using the data from the ongoing Phase III trial (NCT04133311) comparing the efficacy and safety of STN1013001 vs. Latanoprost and with future real-world CUAs upon the availability of STN1013001 on the Italian market.

Automated summary

This study conducted a cost-utility analysis of STN1013001, an innovative latanoprost cationic emulsion, compared to other latanoprost formulations. The results suggest that STN1013001 is potentially highly cost-effective and dominant in treating open-angle glaucoma/ocular hypertension (OAG/OHT) and ocular surface disease (OSD). Further evidence is needed to assess the cost-effectiveness of collecting information on OAG/OHT utilities and OSD-related disutility. Future real-world cost-utility analyses should also consider the availability of STN1013001 in the Italian market.